Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes. It is grouped under the following drug class(es): Pancreatic lipase inhibitors. Its therapeutic use is listed as anti-obesity agents and weight loss agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include oblean, Cametor and cetilistatum. Its PubChem CID is 9952916.
Cetilistat
| CAS No | 282526-98-1 |
|---|---|
| Molecular Formula | C25H39NO3 |
| Molecular Weight | 401.6 g/mol |
| Synonyms | 2-hexadecoxy-6-methyl-3,1-benzoxazin-4-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
The listed CAS number is 282526-98-1.
The listed molecular formula is C25H39NO3.
The listed molecular weight is 401.6 g/mol.
2-hexadecoxy-6-methyl-3,1-benzoxazin-4-one.
The source lists oblean, Cametor and cetilistatum.